What is Osivax?
Osivax is a specialized biopharmaceutical firm dedicated to the creation of transformative, first-in-class pan-respiratory virus vaccines. At the core of its operations is the oligoDOM platform, a self-assembling nanoparticle technology designed to elicit robust T-cell and B-cell immune responses. The company's primary objective is to deliver a single-shot solution capable of neutralizing all strains of influenza and variants of Covid-19. By leveraging this unique scientific approach, Osivax aims to redefine preventative medicine, moving beyond seasonal vaccine limitations toward a more comprehensive, durable, and universal protection model for global public health.
How much funding has Osivax raised?
Osivax has raised a total of $45.6M across 4 funding rounds:
Angel/Seed
$6.5M
Series A
$8.8M
Series B
$10.8M
Other Financing Round
$19.5M
Series A (2019): $8.8M with participation from Anaxago and Noshaq
Angel/Seed (2019): $6.5M led by Pradeyrol Développement
Series B (2025): $10.8M supported by Meiji Seika Pharma
Other Financing Round (2025): $19.5M featuring Biomedical Advanced Research and Development Authority (BARDA
Key Investors in Osivax
Biomedical Advanced Research and Development Authority (BARDA)
BARDA enhances the nation's public health security by facilitating the development of innovative medical countermeasures, including vaccines and therapeutics, from preclinical stages to FDA approval.
Meiji Seika Pharma
A subsidiary of Meiji Holdings, this Japanese pharmaceutical firm specializes in the development and manufacturing of prescription pharmaceuticals, antibiotics, and central nervous system drugs.
Anaxago
Anaxago is a venture capital and investment platform that provides growth capital to innovative companies across various sectors, focusing on high-potential technology and healthcare ventures.
What's next for Osivax?
With the recent infusion of capital, Osivax is well-positioned to accelerate its clinical development pipeline and expand its reach into additional infectious disease indications. The strategic roadmap involves deepening international collaborations and scaling the manufacturing capabilities of its nanoparticle platform. As the company transitions from early-stage research to advanced clinical trials, the focus will remain on securing regulatory milestones and validating the efficacy of its pan-respiratory candidates. This growth trajectory suggests a pivot toward commercialization readiness, supported by a robust network of institutional and governmental partners committed to long-term pandemic preparedness and vaccine innovation.
See full Osivax company page
